Bristol Myers Squibb is breaking off its collaboration and license agreement with uniQure, calling time on a pact that was intended to deliver gene therapies against multiple cardiovascular disease targets.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,